Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Cancer
|
April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Cancer
|
June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Nathalie Rippinger, Christine Fischer, Markus W Haun, et al.
Cancer
|
February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Steven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Cancer
|
March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Glenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Cancer
|
October 13, 2021
Metagenomics and chemotherapy-induced nausea: A roadmap for future research
Sylvia L Crowder, Aasha I Hoogland, Taylor L Welniak, et al.
Cancer
|
December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Eun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Cancer
|
April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer
PierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
Cancer
|
June 20, 2020
Cancer surveillance and distress among adult pathogenic TP53 germline variant carriers in Germany: A multicenter feasibility and acceptance survey
Nathalie Rippinger, Christine Fischer, Markus W Haun, et al.
Cancer
|
February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
Steven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Cancer
|
March 14, 2018
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
Glenwood D Goss, Everett E Vokes, Michael S Gordon, et al.
Cancer
|
October 13, 2021
Metagenomics and chemotherapy-induced nausea: A roadmap for future research
Sylvia L Crowder, Aasha I Hoogland, Taylor L Welniak, et al.
Cancer
|
December 27, 2022
CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study
Eun-Young Kang, Ashley Weir, Nicola S Meagher, et al.
Page
of 9